The Incidence of BRAF V600E Mutations and the Impact of Cladribine Treatment on the Incidence of BRAF V600E Mutations and Survival in Hairy Cell Leukemia Patients: A Case-Control Study Tüylü Hücreli Lösemi Hastalarında BRAF V600E Mutasyonu Sıklığı ve Kladribin Tedavisinin Mutasyon Sıklığı ve Sağkalım Üzerindeki Etkisi: Bir Vaka Kontrol Çalışması

Özmen D., Dağlar Aday A., Nalçacı M., Aktan M.

Turkiye Klinikleri Journal of Medical Sciences, vol.44, no.2, pp.69-75, 2024 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 2
  • Publication Date: 2024
  • Doi Number: 10.5336/medsci.2023-98368
  • Journal Name: Turkiye Klinikleri Journal of Medical Sciences
  • Journal Indexes: Scopus, CAB Abstracts, CINAHL, Veterinary Science Database
  • Page Numbers: pp.69-75
  • Keywords: BRAF V600E mutation, cladribine, Hairy cell leukemia, mortality rate, survival
  • Istanbul University Affiliated: Yes


Objective: Hairy cell leukemia (HCL) is a rare and indolent lymphoproliferative disease characterized by the infiltration of hairy shaped leukemic B cells with specific immunophenotypic features in the bone marrow, spleen and liver resulting in progressive pancytopenia and splenomegaly. Purine analogs are preferred as the first-line treatment for HCL. This study investigates the significance of BRAF V600E mutations in HCL diagnosis and prognosis, focusing on their baseline and post-cladribine treatment incidences and impacts on patient survival. Material and Methods: This retrospective, case-control study comprises HCL patients diagnosed and treated between July 2012 and June 2014. The study group includes 22 HCL patients (newly diagnosed n=10, remission n=12). The control group comprises B-cell chronic lymphoproliferative disease patients (n=10). All HCL patients underwent cladribine treatment. Patient demographics, clinical characteristics, and survival outcomes were recorded. Results: The mean age of the predominantly male (81.8%) study group was 51.1±10.2 years. No significant differences in demographic and clinical features existed between the groups (p>0.05). The incidence of BRAF V600E mutation among HCL patients, initially 69.2%, fell to 20% post-treatment. Yet, no significant disparity in overall survival and mortality rates was found between HCL patients with/without BRAF V600E mutation (p=0.256 and p=0.999). Conclusion: The proportion of HCL patients with BRAF V600E mutations decreased from 69.2% to 20% postcladribine. However, persistence of the mutation didn’t significantly affect HCL patient survival and mortality.